Uwe P.
Education
Medizinische Hochschule Hannover
Dr. med. (MD-PhD), Toxicology-Medicine 1987-01-01 - 1990-01-01
Studienstiftung des Deutschen Volkes
Alumnus, scholar, 1980-10-01 - 1987-09-01
Alliance Manchester Business School
MBA, full time MBA, general 1999-01-01 - 2001-01-01
Medizinische Hochschule Hannover
MD, Human Medicine 1980-01-01 - 1987-01-01Work Experience
Shibakinderzt GmbH
Current
Shibakinderzt GmbH
SwissMediKids
2018-10-01 - 2021-10-01
SwissMediKids
CureVac
2017-01-01 - 2018-09-01
CureVac
CBT Pharmaceuticals Inc.
2016-06-01 - 2016-12-01
CBT Pharmaceuticals Inc.
ActeaVentures GmbH
2014-03-01 - 2016-12-01
ActeaVentures GmbH
Peukert-Advisors, Inc.
2013-12-01 - 2016-12-01
Peukert-Advisors, Inc.
NewVac LTD
2011-10-01 - 2014-07-01
NewVac LTD
Torrey Pines Investment
2011-06-01 - 2014-07-01
Torrey Pines Investment
PharmaSearchEval LLC
2011-04-01 - 2014-07-01
PharmaSearchEval LLC
Onyx Pharmaceuticals, Inc., an Amgen subsidiary
2009-01-01 - 2011-03-01
Onyx Pharmaceuticals, Inc., an Amgen subsidiary
Skills
Summary
Uwe brings more than three decades of applied practical, scientific and commercial medical experience to patients, drug developers, biotech and pharmaceutical companies of all sizes and stages, and to investors in the pharmaceutical/biotech field. He offers broad and two decades of experience in the life sciences BD&L environment and more than 15 years as a practicing physician (board qualified pediatrician, Germany) and scientist to his clients, employers and working teams. Prior to the current commitments Uwe was Area Head Oncolog at CureVac Ag and co-founding Managing Director at ActeaVentures GmbH. He has run an independent US-based boutique business development consulting firm, PharmaSearchEval LLC (later: Peukert-Advisors, Inc.) for more than 6 years. During this endeavor Uwe has temporarily joined the management team of Torrey Pines Investment, Inc. (San Diego, USA) as “SVP Strategic Investment Initiatives”. Prior to working as an independent consultant Uwe held several key roles in BD&L in big pharma (Roche and Eli Lilly), big biotech (Onyx Pharmaceuticals) and small biotech (NewVac LLC) as well as in Venture Capital (Torreypines Investment). During his tenure at Onyx Pharmaceuticals Uwe initiated and lead the technical evaluation/DD resulting in the acquisition of Proteolix Inc (2009, South San Francisco) and the out-licensing of Japanese rights to Carfilzomib to Ono Pharmaceuticals (2010, Osaka/Japan). In his time at Eli Lilly & Co Uwe triggered and completed the technical and business evaluation leading to the acquisition of Imclone ($6.3 billion deal value, 2008). At Roche, Uwe was fully accountable for the opt-in business case supporting the decision to license Avastin from Genentech to Roche in 2003.
